Comparing the i31-SLNB and the MIA Nomogram for Sentinel Lymph Node Biopsy Positivity Prediction in Cutaneous Melanoma: A Prospective Cohort Analysis - Summary - MDSpire
Advertisement
Comparing the i31-SLNB and the MIA Nomogram for Sentinel Lymph Node Biopsy Positivity Prediction in Cutaneous Melanoma: A Prospective Cohort Analysis
To compare the accuracy of the i31-SLNB and MIA nomogram in predicting sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM) being considered for sentinel lymph node biopsy (SLNB).
Approach:
Study Design: The study was a prospective, multicenter analysis comparing the i31-SLNB and MIA nomogram among patients enrolled in the DECIDE study across 30 sites in the USA.
Testing Methodology: The i31-SLNB combines a 31-gene expression profile score with clinicopathologic factors to assess SLN-positivity risk.
Key Findings:
The i31-SLNB more accurately identified patients at high and low risk of SLN positivity compared to the MIA nomogram.
Using i31-SLNB can help low-risk patients avoid unnecessary SLNB, thus reducing surgery-associated morbidities.
Interpretation:
The i31-SLNB provides a more reliable prediction of SLN positivity than the MIA nomogram, potentially allowing for better patient selection for SLNB.
Limitations:
The MIA nomogram has not been validated in a prospective study.
The MIA nomogram requires melanoma histologic subtype, which is unavailable for approximately half of patients in the USA.
Conclusion:
The study suggests that the i31-SLNB may be a superior tool for predicting SLN positivity in CM patients, potentially reducing unnecessary procedures.
